GlobeNewswire

Clinical Study: Patient-Specific Total Knee Replacement with Conformis Technology Is More Cost-Effective Than with Leading Off-the-Shelf Implants

Share

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.

BILLERICA, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that an independent, retrospective review of hospital data has concluded that Conformis iTotal® knee replacement technology is more cost-effective than leading traditional, off-the-shelf implants. Importantly, this study was independently performed with no sponsorship or funding from Conformis.

The new abstract was presented by authors at the Orthopaedic Research Society 2021 Annual Meeting (ORS 2021 Annual Meeting), held in February 2021:

Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant, Navin Fernando MD, Ann Chancellor CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021 Proceedings of Orthopaedic Research Society, Paper 0980

The retrospective review was performed at a single medical institution between 2016 and 2019 using a financial database and electronic health records.

Patient demographics, total direct costs, length of stay (LOS) and opioid use were all investigated. Two groups were evaluated for procedures performed by a single surgeon, Dr. Paul Manner, MD, Joint Replacement/Hip and Knee Arthritis Professor in the Department of Orthopaedics and Sports Medicine at the University of Washington in Seattle. Procedures for a control group were performed by a second surgeon, Dr. Navin Fernando:

  • Primary group – patient-specific implant (Conformis iTotal®)
  • Comparison group – traditional implant (Zimmer Persona®)
  • Control group – traditional implant (Stryker Triathlon®) performed by second surgeon

"We've been very pleased with the early outcomes for patients with the Conformis knee. Patients report that the knee feels more like a normal, healthy joint; they recover more quickly, and are back to regular activity substantially faster than with traditional, off-the-shelf implants,” said Dr. Paul Manner. “We found that the episode of care cost is substantially less with the Conformis knee because patients spent less time in the hospital, and because the surgery can be performed in less time. Everyone wins.”

“It is very gratifying to see Conformis technology once again demonstrate its superior performance, as presented at the ORS 2021 Annual Meeting,” said Mark Augusti, President and Chief Executive Officer, Conformis, Inc. “By designing and manufacturing Conformis iTotal® knee replacement implants to fit each individual’s unique anatomy, patients, surgeons, and medical facilities benefit from expedited surgeries and shorter hospital lengths of stay. Conformis iTotal® implants help to relieve chronic joint pain, while also driving savings for hospitals and insurance providers.”

The median patient age was 66 years old, and the median BMI was 31 for the three groups.

Mean LOS analysis:

  • 1.35 days for Conformis iTotal® patients
  • 1.99 days for Zimmer Persona® patients
  • 1.83 for Stryker Triathlon® patients

Total direct costs analysis:

  • $9,341 for Conformis iTotal® patients (savings of $1,006 to $1,263 per patient)
  • $10,347 for Zimmer Persona® patients
  • $10,604 for Stryker Triathlon® patients

There was no apparent difference in morphine equivalent dose use amongst the three groups.

The study concludes that total direct costs for hospital admissions appear to be more cost-effective with the Conformis iTotal® System, and variables such as operative time and LOS also appear to favor a patient-specific implant over traditional, off-the-shelf implants.

Three other comparative studies published between 2017 and 2019 also demonstrate that Conformis iTotal® implants drive savings for hospitals and insurance companies:

  • O’Connor, Mary, and Blau, Brittany, “Assessing the Economic Value of Custom Implants." American Health & Drug Benefits. 2019, Vol.12, No. 2.
  • Richard G. Buch, M.D., Robert W. Eberle, Jason Davis, M.D., and Rylie Buch, MS, “Does Implant Design Affect Hospital Metrics and Patents Outcomes? TKA Utilizing a ‘Fast-Track’ Protocol.” Reconstructive Review. 2019, Vol. 9 No. 1.
  • Culler et al., “Comparison of Adverse Event Rates and Hospital Costs Between Customized Individually Made Implants and Standard Off-the-Shelf Implants for Total Knee Arthroplasty.” Arthroplasty Today 2017.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Infant Bacterial Therapeutics receives additional patent protection in China15.4.2021 19:00:00 CEST | Press release

Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. IBT recently received similar patent protection in Japan. This patent increases the existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug Exclusivity and biological data protection already established in the USA and EU. The Chinese patent expires in 2036 and the IBP-9414 product covered by this patent is intended to be mark

Infant Bacterial Therapeutics erhåller ytterligare patentskydd i Kina15.4.2021 19:00:00 CEST | Pressemelding

Infant Bacterial Therapeutics AB (IBT) tillkännager idag att det Kinesiska patentmyndigheten har beslutat utfärda ett godkännande av IBTs patentansökan: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar av Lactobacillus reuteri inklusive IBP-9414. IBP-9414 är den läkemedelskandidat IBT utvecklar i fas III för förebyggande av nekrotiserande enterokolit hos prematura spädbarn och för förbättrat födointag hos dessa barn. Uppfinningen omfattar ett unikt sätt att aktivera bakterien och patentansökningar behandlas samtidigt i flera viktiga framtida marknader, inklusive USA och EU. IBT har sedan tidigare erhållit motsvarande patentskydd i Japan. Patentet styrker det existerande skyddet för IBTs läkemedelskandidat IBP-9414 för vilken både särläkemedelsstatus och dataskydd för biologiska produkter beviljats i USA och EU. Det kinesiska patentet sträcker sig till 2036 och IBP-9414 avses att marknadsföras i Kina när marknadsgodkännande erhållits. “Vi är mycket glada över

REPURCHASE OF SHARES15.4.2021 18:30:00 CEST | Press release

REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has successfully completed its share buyback programme. Flow Traders purchased 8,903 of its own shares on 15 April 2021 at an average price of €37.22 in accordance with the share buyback programme announced on 12 February 2021. These repurchases were made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €0.3 million. The total number of shares purchased under this programme is 725,577 shares at an average price of €34.45 for a total consideration of €25.0 million. 2,285,243 shares were held in treasury as at 15 April 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Tr

Stolt-Nielsen Elects Janet Ashdown to Board of Directors15.4.2021 18:12:30 CEST | Press release

LONDON, April 15, 2021 - Stolt-Nielsen Limited (Oslo Børs: SNI) announced today that Janet Ashdown has been appointed to the Board of Directors of Stolt-Nielsen Limited. "Ms. Ashdown’s extensive industry experience, has given her good exposure to some of Stolt-Nielsen’s key markets. I am confident that she will bring constructive challenge and strategic insights to the Board," said CEO Niels G. Stolt-Nielsen. The Board of Directors of SNL received approval at the Company's Annual General Meeting held today to fill the vacancy. With the addition of Ms. Janet Ashdown, the Stolt-Nielsen Board now has eight members, five of which are independent. Ms. Ashdown is a highly-experienced Director and has served on the boards of four FTSE 250 companies across a broad range of industrial sectors. She joined BP plc in 1980, and during her 30 year career there had excellent exposure to some of Stolt-Nielsen’s key markets. In her last role with BP she was responsible for a £20bn network of fuel outle

Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas15.4.2021 17:45:00 CEST | Press release

KEY FIGURESRevenue 1st quarter 2021 €266.5 millionGrowth at constant exchange rates and scope 1 +22.6% of which companion animals +25.1% food-producing animals +19.2%Growth at constant exchange rates +12.3% Total growth +7.6% +17.5%excl. Sentinel 1 Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year, and by excluding sales of Sentinel for the two financial years in question. Quarterly consolidated revenue Our revenue in the first quarter amounted to €266.5 million, with a substantial increase of +17.5% excluding Sent

NetJets Shares First Biannual Global Sustainability Program Progress Update15.4.2021 16:09:19 CEST | Press release

The World's Largest Private Aviation Company Furthers Its Commitment to Sustainable Aviation COLUMBUS, Ohio, April 15, 2021 (GLOBE NEWSWIRE) -- NetJets, the leader in private aviation with more than 760 aircraft worldwide, today releases its first biannual update following the launch of its expanded Global Sustainability Program in October 2020. Since the program announcement, NetJets has taken its commitment to sustainability a step further, acquiring a stake in WasteFuel®, a next generation waste-to-fuel business that transforms landfill waste into sustainable aviation fuel (SAF). NetJets will also purchase 100 million gallons of SAF over the next decade. This represents one of the largest SAF offtakes in the aviation industry and by far the largest in private aviation. In addition to sustainable fuel, NetJets’ initiative focuses on consumer and corporate carbon offsetting. This includes offsetting NetJets’ administrative and training flights, as well as its two corporate offices in

Rovio Entertainment's new team-based RPG Darkfire Heroes releases worldwide today on iOS and Android15.4.2021 15:00:00 CEST | Press release

Rovio’s new team-based RPG Darkfire Heroes releases worldwide today on iOS and Android Espoo, Finland – 15 April 2021 – Build a powerful party of heroes and embark on an adventure for the ages in Rovio Entertainment’s newest game, Darkfire Heroes. The game is available to download for free now worldwide on the App Store and Google Play after a successful soft launch period in select regions. Darkfire Heroes is a strategic team-based RPG set in a rich fantasy world. Players must assemble a powerful team of heroes to take on hordes of baddies. There is a collection of over 60 heroes at launch, each with their own unique style, abilities, and attacks. Choose the right heroes to take into battle, outfit them with powerful gear, and unleash powerful spells against enemies. There’s a substantial campaign for those looking for a single-player experience, but also a PvP arena for players that crave a bit of competition. A new IP in Rovio’s game portfolio, Darkfire Heroes is the first release f